Glenmark Pharmaceuticals (GLENMARK.NS) Stock Price

Glenmark Pharmaceuticals Price

NSE·CLOSED
2,677.00
​
Market closed

Over the last 19 years Glenmark Pharmaceuticals grew revenue by 14.6% annually, reaching 167.11 B INR. Earnings per share have grown at 7.8% per year over the last 19 years. For Glenmark Pharmaceuticals, the net margin of 8.1% is broadly stable versus 7.7% a few years ago. At today's price the dividend yield works out to roughly 0.19%. The payout ratio is around 15% of earnings. The dividend has grown at 8.3% per year over the past 19 years. The consensus 12-month price target for Glenmark Pharmaceuticals is 2,305.20 INR, about 13.9% below where the stock trades today. Of 17 analysts, 14 rate the stock a buy — an overall Buy consensus.

Glenmark Pharmaceuticals stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Glenmark Pharmaceuticals business model & stock analysis

Glenmark Pharmaceuticals Ltd is a global pharmaceutical company that specializes in the development, manufacturing, and marketing of pharmaceutical products. The company was founded in 1977 and has since become one of the largest pharmaceutical companies in India. Glenmark is headquartered in Mumbai, India, and operates in over 80 countries worldwide. Glenmark specializes in the research and development of innovative, high-quality medicines. The company produces a wide range of medications in various therapeutic areas such as dermatology, respiratory diseases, pain management, gastroenterology, oncology, and many others. Glenmark has several subsidiaries, including Glenmark Generics and Glenmark Life Sciences, which focus on generic medicines and research and development. Glenmark Pharmaceuticals' business model is based on the continuous research, development, and marketing of innovative medicines that meet the medical needs of patients worldwide. The company has its own R&D department, which focuses on the identification and exploration of new products and technologies. In addition, Glenmark has formed strategic partnerships with leading multinational pharmaceutical companies such as Teva, Sanofi, and Merck KGaA to jointly develop and market innovative medicines. Glenmark also has a strong presence in the generic market and produces high-quality generics in various therapeutic areas. Glenmark Pharmaceuticals is divided into various business segments, including branded products, generics, APIs, and research and development. In the branded products segment, Glenmark has a strong presence in Asia, Africa, and Latin America, where the company distributes innovative medicines in various therapeutic areas. In the generics segment, Glenmark has a wide portfolio of high-quality generic medicines in various therapeutic areas. Glenmark is also involved in the manufacture of APIs (Active Pharmaceutical Ingredients) and supplies high-quality APIs to leading pharmaceutical companies worldwide. Glenmark offers a wide range of products tailored to the needs of patients in various therapeutic areas. Some of Glenmark's well-known products include Ondansetron, a medicine for nausea and vomiting; Candid, a topical treatment for fungal infections; and Perfinzek, a painkiller. The company also has a strong presence in dermatology, offering a variety of products for the treatment of skin conditions such as acne, psoriasis, and eczema. In recent years, Glenmark has also focused on the development of biopharmaceuticals. The company has a strong pipeline of biopharmaceuticals for the treatment of cancer, inflammatory diseases, and other illnesses. Glenmark also has a strong presence in the research and development of medicines for rare diseases and is targeting several rare conditions. Overall, Glenmark Pharmaceuticals holds a strong position in the global pharmaceutical industry. The company specializes in the development and marketing of innovative medicines for patients worldwide and offers a wide range of products in various therapeutic areas. Glenmark also has a strong presence in the generic market and a growing pipeline of biopharmaceuticals for the treatment of cancer, inflammatory diseases, and other illnesses.

Frequently asked questions about Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd. operates on a highly efficient business model focused on the development, manufacturing, and distribution of innovative pharmaceutical products. The company follows a research-oriented approach and endeavors to bring affordable, high-quality drugs to patients across the globe. Glenmark Pharmaceuticals specializes in the areas of dermatology, respiratory, oncology, and several other therapeutic segments. By leveraging its strong R&D capabilities and global manufacturing infrastructure, the company aims to address unmet medical needs and improve healthcare accessibility. Glenmark Pharmaceuticals' business model emphasizes continuous innovation, strategic partnerships, and expansion into new markets, reinforcing its position as a leading pharmaceutical player in the industry.

Glenmark Pharmaceuticals Ltd is primarily active in the pharmaceutical industry.

The main competitors of Glenmark Pharmaceuticals Ltd in the market include companies like Sun Pharmaceutical Industries Ltd, Cipla Ltd, Dr. Reddy's Laboratories Ltd, and Lupin Ltd. These companies are also leading players in the pharmaceutical industry and compete with Glenmark Pharmaceuticals in terms of product offerings, market share, and innovation.

Glenmark Pharmaceuticals Ltd. is a renowned pharmaceutical company with a rich history and background. Founded in 1977 by Gracias Saldanha, it started as a generic drug manufacturer in Mumbai, India. Over the years, Glenmark has grown into a global player in the pharmaceutical industry, focusing on research and development of innovative therapeutics. The company has a diverse portfolio, covering various therapeutic areas such as dermatology, respiratory, and oncology. Glenmark has consistently shown its commitment to quality and affordability, making healthcare accessible to a larger population. With its global presence and cutting-edge research, Glenmark Pharmaceuticals Ltd. continues to make significant contributions to the healthcare industry.

Some significant milestones achieved by Glenmark Pharmaceuticals Ltd include: 1. The development and commercialization of several innovative and patent-protected drugs in various therapeutic categories. 2. Successful market expansion globally, with presence in over 80 countries and a strong focus on emerging markets. 3. Consistent growth in revenue and profitability over the years, establishing a strong financial position in the pharmaceutical industry. 4. Launching of the first biosimilar monoclonal antibody, marking a breakthrough in the field of biotherapeutics. 5. Collaborations and partnerships with renowned pharmaceutical companies, enabling the company to leverage expertise and expand its product portfolio. 6. Achieving regulatory approvals for various drugs, demonstrating compliance with international quality standards. 7. Initiatives for research and development, encouraging innovation and driving the company's future growth.

Glenmark Pharmaceuticals Ltd primarily operates in various countries and regions worldwide. The company has a significant presence in India, where it is headquartered and has a strong market presence. Additionally, Glenmark Pharmaceuticals has established operations and a market presence in several other countries, including the United States, Europe, Latin America, and Asia-Pacific regions. With its global footprint, Glenmark Pharmaceuticals continues to expand its reach and deliver innovative healthcare solutions to patients around the world.

Glenmark Pharmaceuticals Ltd represents a strong commitment to innovation, quality, and patient-centricity. The company focuses on delivering affordable and accessible healthcare solutions for people worldwide. With a vision to be a leading global pharmaceutical company, Glenmark Pharmaceuticals embraces a corporate philosophy centered around integrity, transparency, and ethical practices. By continually investing in research and development, Glenmark Pharmaceuticals strives to develop new and improved treatments to address unmet medical needs. Through its relentless efforts, the company aims to make a positive impact on the lives of patients and contribute to the growth and well-being of the healthcare industry.

Analysts currently set an average price target of 2,216.96 INR for the Glenmark Pharmaceuticals stock (median: 2,305.20 INR), implying -15.2 % versus the latest price. The consensus is based on 17 analyst ratings.

17 analysts currently rate the Glenmark Pharmaceuticals stock: 14 recommend buying, 2 holding and 1 selling.

Converted at the current exchange rate, the Glenmark Pharmaceuticals share trades at 26.12 EUR (2,677.00 INR).

The Glenmark Pharmaceuticals share (GLENMARK.NS) is listed on 2 stock exchanges, including: NSE (Indien) (GLENMARK.NS).

Glenmark Pharmaceuticals Ltd is a multinational pharmaceutical company based in Mumbai, India. The company operates in several sectors, including the development, manufacturing, and marketing of prescription drugs, generic medicines, active pharmaceutical ingredients, and over-the-counter products. In the area of prescription medicines, Glenmark has obtained approvals for a wide range of products that can be used to treat various diseases and disorders. These include therapies for respiratory diseases, dermatology, ophthalmology, oncology, pain management, women's healthcare, and many more. An important aspect of their business strategy is to continuously invest in research and development to expand and improve their product range. Glenmark has also specialized in the manufacturing of generic medicines and offers an extensive range of generic drugs. These include well-known brand-name medicines such as Atorvastatin, Pioglitazone, Sertraline, Olanzapine, and a variety of other medications. Glenmark has a strong presence in numerous countries around the world and has established itself as a reliable, high-quality supplier of generic medicines. Another important area of Glenmark Pharmaceuticals is the manufacturing of active pharmaceutical ingredients (APIs). Here, the company produces high-quality ingredients that are used in a variety of medications, from antibiotics and analgesics to antidepressants and cardiovascular drugs. Glenmark has multiple manufacturing facilities that operate according to the strictest international standards. In addition to prescription drugs, generic medicines, and APIs, Glenmark also produces a range of over-the-counter products. These can be purchased without a prescription and include a wide variety of products, such as painkillers, cough and cold remedies, multivitamin supplements, antacids, and anti-fungal products. Glenmark has carefully selected portfolio of OTC products that are available in many countries. The business strategy of Glenmark Pharmaceuticals is focused on growth and expansion. The company pursues an aggressive acquisition strategy and has made several acquisitions in recent years to expand its reach and capabilities. To further strengthen business development, Glenmark places great emphasis on innovation and research and development. The company invests a significant portion of its revenue in R&D activities to develop new groundbreaking therapies and medications. Glenmark's products are characterized by high quality, reliability, and effectiveness and are available in many countries around the world. The company has a carefully curated portfolio of products tailored to the needs of patients and the healthcare market. Through its investments in research and development and its acquisitions, Glenmark continuously strives for growth and expansion and is on track to take a leading role in the global pharmaceutical industry.

The revenue of Glenmark Pharmaceuticals is 167.11 B INR. This figure is based on current financial data and reflects the company's business performance.

The profit of Glenmark Pharmaceuticals is 13.62 B INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Glenmark Pharmaceuticals is currently 55.52. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Glenmark Pharmaceuticals stock.

The price-to-sales ratio (P/S) of Glenmark Pharmaceuticals is currently 4.52. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Glenmark Pharmaceuticals stock.

The Eulerpool Quality Score for Glenmark Pharmaceuticals is 6/10.

The ISIN of Glenmark Pharmaceuticals is INE935A01035. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Glenmark Pharmaceuticals is GLENMARK.NS. The ticker symbol is used to trade Glenmark Pharmaceuticals shares on the stock exchange.

Fair ValueTerminal
2,302.22 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
10.84 M INR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
INR
Initial public offering
Dec 10, 1999
ISIN
INE935A01035
Cusip
Y2711C144
Sedol
6698755
Market capitalization
755.48 B INRMega Cap
52-Week Range
PEG
4.95
P/E ratio
P/Ee 2027
33.02
P/Ee 2028
26.72
P/Ee 2029
24.00
P/S
P/Se
4.49
EV/EBIT
18.49
P/B Ratio
7.19
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
12.96 %
Dividend
Dividend yield
0.19 %
Est. Dividend Yield
0.09 %
Payout Ratio
14.90 %
Dividend growth Ø5Y
—
Dividend payments per year
2
Dividend paid since
17 years
Dividend not reduced since
17 years
Dividend increased since
1 year
Dividend withholding tax
20.00 %
Last updated Nov 19, 2026, 3:40 AM

Glenmark Pharmaceuticals Peer Group

Glenmark Pharmaceuticals Ticker

BSE · GLENMARK.BONSE INDIA · GLENMARK.NS

Glenmark Pharmaceuticals FIGI

GNP:IN · BBG000BJ3TJ8GNP:IB · BBG000BJ3V03GNP:IS · BBG000BJ3VG6GNP:IG · BBG003NW0Q54GNPINR:XB · BBG00JRN9MR1GNPINR:XS · BBG00JRN9N62